Enzo Biochem Reports Long Term Retention Of Antisense RNA In Phase I Study Of HIV-1 Infected Subjects; Updated Report To International AIDS Conference Calls Results “Significant”

Reporting here at the 16th International AIDS Conference, Enzo Biochem, Inc. (NYSE:ENZ) described the results of long term follow-up studies of its StealthVector(R) HGTV43(TM) gene medicine as “significant” and “perhaps unique.” HIV-1 infected subjects treated with the proprietary retrovirus-based vector showed long term presence of the engineered CD34+ stem cells as well as a long term presence of engineered CD4+ immune cells in circulation. The Phase I clinical trial took place at the University of California San Francisco.